ネクセラファーマの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/03/16 | 2,420 | 2,440 | 2,356 | 2,401 | -33 | -1.4% | 1,209,100 |
2023/03/15 | 2,441 | 2,453 | 2,377 | 2,434 | +43 | +1.8% | 1,493,000 |
2023/03/14 | 2,380 | 2,437 | 2,374 | 2,391 | -25 | -1% | 1,263,700 |
2023/03/13 | 2,410 | 2,441 | 2,362 | 2,416 | -44 | -1.8% | 1,033,600 |
2023/03/10 | 2,499 | 2,568 | 2,427 | 2,460 | -3 | -0.1% | 2,477,000 |
2023/03/09 | 2,417 | 2,469 | 2,404 | 2,463 | +126 | +5.4% | 3,743,100 |
2023/03/08 | 2,288 | 2,352 | 2,270 | 2,337 | +34 | +1.5% | 843,300 |
2023/03/07 | 2,310 | 2,345 | 2,292 | 2,303 | -19 | -0.8% | 541,800 |
2023/03/06 | 2,360 | 2,363 | 2,315 | 2,322 | -6 | -0.3% | 692,000 |
2023/03/03 | 2,240 | 2,375 | 2,240 | 2,328 | +102 | +4.6% | 1,740,200 |
2023/03/02 | 2,180 | 2,235 | 2,158 | 2,226 | +78 | +3.6% | 847,900 |
2023/03/01 | 2,207 | 2,223 | 2,136 | 2,148 | -58 | -2.6% | 1,000,100 |
2023/02/28 | 2,261 | 2,261 | 2,184 | 2,206 | -5 | -0.2% | 1,141,600 |
2023/02/27 | 2,309 | 2,309 | 2,199 | 2,211 | -137 | -5.8% | 1,940,200 |
2023/02/24 | 2,368 | 2,389 | 2,337 | 2,348 | -23 | -1% | 714,400 |
2023/02/22 | 2,421 | 2,421 | 2,360 | 2,371 | -73 | -3% | 1,069,100 |
2023/02/21 | 2,445 | 2,492 | 2,411 | 2,444 | +10 | +0.4% | 750,100 |
2023/02/20 | 2,478 | 2,478 | 2,413 | 2,434 | -57 | -2.3% | 872,600 |
2023/02/17 | 2,570 | 2,577 | 2,471 | 2,491 | -106 | -4.1% | 1,546,400 |
2023/02/16 | 2,435 | 2,609 | 2,395 | 2,597 | +169 | +7% | 2,191,100 |
2023/02/15 | 2,340 | 2,455 | 2,305 | 2,428 | +79 | +3.4% | 1,327,400 |
2023/02/14 | 2,332 | 2,349 | 2,320 | 2,349 | +30 | +1.3% | 452,600 |
2023/02/13 | 2,326 | 2,347 | 2,291 | 2,319 | -50 | -2.1% | 686,400 |
2023/02/10 | 2,404 | 2,423 | 2,365 | 2,369 | -44 | -1.8% | 514,800 |
2023/02/09 | 2,422 | 2,434 | 2,387 | 2,413 | -24 | -1% | 530,100 |
2023/02/08 | 2,445 | 2,447 | 2,402 | 2,437 | +11 | +0.5% | 353,800 |
2023/02/07 | 2,371 | 2,435 | 2,369 | 2,426 | +57 | +2.4% | 501,200 |
2023/02/06 | 2,426 | 2,429 | 2,364 | 2,369 | -37 | -1.5% | 609,900 |
2023/02/03 | 2,421 | 2,440 | 2,392 | 2,406 | -20 | -0.8% | 692,800 |
2023/02/02 | 2,440 | 2,449 | 2,411 | 2,426 | -21 | -0.9% | 692,700 |
2023/02/01 | 2,475 | 2,519 | 2,439 | 2,447 | -5 | -0.2% | 989,200 |
2023/01/31 | 2,419 | 2,459 | 2,403 | 2,452 | +29 | +1.2% | 603,000 |
2023/01/30 | 2,405 | 2,459 | 2,398 | 2,423 | -16 | -0.7% | 605,100 |
2023/01/27 | 2,430 | 2,457 | 2,382 | 2,439 | -21 | -0.9% | 1,074,700 |
2023/01/26 | 2,445 | 2,502 | 2,431 | 2,460 | +15 | +0.6% | 952,000 |
2023/01/25 | 2,426 | 2,459 | 2,394 | 2,445 | -5 | -0.2% | 807,600 |
2023/01/24 | 2,443 | 2,470 | 2,401 | 2,450 | -25 | -1% | 1,390,800 |
2023/01/23 | 2,375 | 2,515 | 2,371 | 2,475 | +121 | +5.1% | 3,058,100 |
2023/01/20 | 2,262 | 2,364 | 2,253 | 2,354 | +114 | +5.1% | 2,513,600 |
2023/01/19 | 2,160 | 2,264 | 2,158 | 2,240 | +72 | +3.3% | 1,566,500 |
2023/01/18 | 2,122 | 2,174 | 2,084 | 2,168 | +105 | +5.1% | 1,385,300 |
2023/01/17 | 2,170 | 2,179 | 2,057 | 2,063 | -116 | -5.3% | 1,526,200 |
2023/01/16 | 2,251 | 2,268 | 2,176 | 2,179 | -85 | -3.8% | 1,143,100 |
2023/01/13 | 2,250 | 2,288 | 2,245 | 2,264 | -2 | -0.1% | 538,900 |
2023/01/12 | 2,290 | 2,299 | 2,246 | 2,266 | -17 | -0.7% | 711,000 |
2023/01/11 | 2,258 | 2,310 | 2,249 | 2,283 | +62 | +2.8% | 1,411,500 |
2023/01/10 | 2,209 | 2,249 | 2,195 | 2,221 | +4 | +0.2% | 1,035,700 |
2023/01/06 | 2,177 | 2,226 | 2,167 | 2,217 | +60 | +2.8% | 1,096,000 |
2023/01/05 | 2,148 | 2,179 | 2,113 | 2,157 | +56 | +2.7% | 1,319,900 |
2023/01/04 | 2,161 | 2,176 | 2,091 | 2,101 | -37 | -1.7% | 1,031,500 |
551~
600
件表示中 / 5111件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ネクセラファーマ | 90,500円 | +20.3% | - | 0.00% | 160.46倍 | 1.20倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
杏林製薬 | 148,000円 | -2.4% | -52.3% | 3.85% | 17.71倍 | 0.63倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 217,700円 | +4.1% | -3.1% | 2.66% | 18.96倍 | 1.65倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
JCRファーマ | 55,400円 | +14.3% | - | 3.61% | 22.50倍 | 1.44倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
あすかHD | 232,100円 | +16.9% | +33.2% | 2.37% | 12.66倍 | 1.01倍 |
|
武田と親密。婦人科領域に強い。先発品比率引き上げに注力。21年春にあすか製薬が持株会社化 |
市場注目の銘柄
チャート関連のコラム